Separately, Vivus has now succumbed to shareholder pressure and begun holdings talks with large drugmakers to market its Qsymia diet pill, which has so far failed to live up to its promise, despite becoming the first commercially available prescription diet pill to be approved by the FDA in more than a decade.
To some, this may appear to be a big plus for Vivus, which has so far failed to live up to its promise, despite selling what is the first commercially available prescription diet pill to be approved by the FDA in more than a decade.